Skip to main content

Baxter International Drug Compounding revenue

  • BAX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$25.81+0.27%Close 13 Nov 2026 · Market value $13.28B

Drug Compounding revenue at Baxter International came to $320.0M for the quarter to 31 Mar 2026, up 30.1% from a year earlier.

As Baxter International reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Apr 2026.

By quarter

$218.0MJun 2023$229.0MSep 2023$237.0MDec 2023$250.0MMar 2024$261.0MJun 2024$267.0MSep 2024$260.0MDec 2024$246.0MMar 2025$280.0MJun 2025$299.0MSep 2025$316.0MDec 2025$320.0MMar 2026
Baxter International Drug Compounding revenue, every reported period
Period endingDrug Compounding revenueChange on a yearFiled
31 Mar 2026$320.0Mup 30.1%30 Apr 2026
31 Dec 2025$316.0Mup 21.5%12 Feb 2026
30 Sep 2025$299.0Mup 12.0%4 Nov 2025
30 Jun 2025$280.0Mup 7.3%5 Aug 2025
31 Mar 2025$246.0Mdown 1.6%6 May 2025
31 Dec 2024$260.0Mup 9.7%21 Feb 2025
30 Sep 2024$267.0Mup 16.6%12 Nov 2024
30 Jun 2024$261.0Mup 19.7%6 Aug 2024
31 Mar 2024$250.0Mup 14.7%2 May 2024
31 Dec 2023$237.0M—8 Feb 2024
30 Sep 2023$229.0Mup 14.5%2 Nov 2023
30 Jun 2023$218.0M—27 Jul 2023
31 Mar 2023$218.0M—27 Apr 2023
30 Sep 2022$200.0M—27 Oct 2022

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Baxter International: Infusion Therapies & Platforms revenue · Infusion Therapies & Technologies revenue · Care & Connectivity Solutions revenue · Advanced Surgery revenue · Front Line Care revenue · Injectables & Anesthesia revenue · Medical Products & Therapies revenue · Healthcare Systems & Technologies revenue · Pharmaceuticals revenue · United States revenue · International revenue · financial statements

Every KPI and segment of BAX, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.